Form 8-K - Current report:
SEC Accession No. 0001193125-23-164423
Filing Date
2023-06-09
Accepted
2023-06-09 16:01:53
Documents
14
Period of Report
2023-06-07
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d503566d8k.htm   iXBRL 8-K 53377
2 EX-3.1 d503566dex31.htm EX-3.1 17374
  Complete submission text file 0001193125-23-164423.txt   239574

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA achv-20230607.xsd EX-101.SCH 2789
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20230607_def.xml EX-101.DEF 13898
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20230607_lab.xml EX-101.LAB 23170
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20230607_pre.xml EX-101.PRE 14764
8 EXTRACTED XBRL INSTANCE DOCUMENT d503566d8k_htm.xml XML 5476
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 231005146
SIC: 2835 In Vitro & In Vivo Diagnostic Substances